Global healthcare is amidst a digital revolution!
Development of digital health software, tools and devices create not only value, but also enhance patient outcomes, building new sustainable business models for those embracing change. However, the paradigm shift from traditional pharma to companion and standalone digital therapeutics is complex, with many barriers to adoption.
Attend this conference to explore the challenges and opportunities related to the adoption, implementation and transition required to incorporate digital therapeutics into the commercial pharma portfolio.
Learn From Our Digital Health Experts
Zina Manji
M.S., PharmD, RAC, Senior Director, Regulatory Affairs Lead – Innovation, US
GSK
Bert Hartog
Research and Development Operations, Senior Director Clinical Innovation
The Janssen Pharmaceutical Companies of Johnson & Johnson
Mikaela K Odlander
Director and Head of Digital Therapeutics EMEAA
Orexo Pharmaceuticals
Dominick Kennerson
Digital & Commercial Innovation, Global Head G4A Digital Health Partnerships
Bayer
Gergely Vertes
Medical Device Innovation Lead
UCB
Smit Patel
Director of Digital Medicine
DIME, Digital Medicine Society
Rick Bartels
Managing Partner
DTxCC | Digital Therapeutics Commercialization Consultants
Dr Sachin S Shah
Digital Biomarker Lead
GSK
Dr Deepti Sodhi Jaggi
Chief Strategy Officer (CSO)
Better Therapeutics
Emily Luvison
Principal Lead Cybersecurity Compliance for Digital Health Technologies
Genentech
Loreen Brown
Global Head of Patient Support
Medocity
Dario Motti
PhD, Global Principal Scientist, Digital Health Technologies
Roche
Megan Coder
VP of Global Policy
Digital Therapeutics Alliance
Basker Gummadi
Senior Director Digital Therapeutic
Bristol Myers Squibb
Elefteria Pissadaki
PhD, Manager, Systems Neuroscientist, Biogen Digital Health (BDH)
Biogen
Jessica Shull
Director of Digital Therapeutics
Vicore Pharma
Walter Greenlead PhD
Neuroscientist, Virtual Reality, and Digital Health Expert, Virtual Human Interaction Lab
Stanford University
This event will provide you with the necessary tools to:
- Create and refine the roadmap for successful development, integration and implementation of digital therapeutics within the current pharma portfolio
- Prepare for the digital age, convey the message, gain buy-in and develop the mindset required to embrace digital medicine at scale
- Navigate the regulatory, reimbursement and commercialization landscape of DTx, to define suitable routes to market and effective business models
- Leverage real world evidence to create value with digital health tools, unlocking sustainable opportunities for pharma, patients and stakeholders
- Develop digital therapeutics that facilitate adherence, improve efficacy, enhance outcomes and reduce costs in administering healthcare as standalone or companion solutions
- Create strategic partnerships by identifying and selecting suitable partners and solutions providers who can add value and accelerate the advancement of DTx
Who Should Attend:
Digital Therapeutics Global is designed for VP’s, Directors, Heads, Managers and Scientists from:
- Digital Therapeutics / DTx
- Digital Health / Digital Medicine / Personalized Medicine / Precision Medicine
- Digital Healthcare / Connected Health
- Clinical Innovation / Clinical Development / Clinical R&D
- Digital Patient Health / Patient- Centricity / Patient Outcomes / Patient Insights / Real World Evidence (RWE)
- Regulatory Affairs / Medical Affairs
- Emerging Technology / Innovation
- Commercial Innovation
- Data Science & Analytics
- Artificial Intelligence (AI) / Machine Learning (ML)